Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation

被引:62
作者
Contant, CME
Menke-Pluijmers, MBE
Seynaeve, C
Meijers-Heijboer, EJ
Klijn, JGM
Verhoog, LC
Wai, RTJ
Eggermont, AMM
van Geel, AN
机构
[1] Univ Rotterdam Hosp, Dr Daniel Denhoed Canc Ctr, Dept Surg Oncol, NL-3075 EA Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, Dr Daniel Denhoed Canc Ctr, Dept Med Oncol, NL-3075 EA Rotterdam, Netherlands
[3] Zuiderziekenhuis, Rotterdam, Netherlands
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2002年 / 28卷 / 06期
关键词
prophylactic mastectomy; immediate breast reconstruction; silicone prosthesis;
D O I
10.1053/ejso.2002.1279
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Aim: Women with a proven BRCA1 or BRCA2 germ-line mutation or with a 50% risk of carrying the mutation, have an increased risk of breast cancer. Regular surveillance, chernoprevention or prophylactic mastectomy (PM) are options to detect breast cancer at an early stage or to reduce the risk. We describe the management of women who have opted for PM, the postoperative complications of PM, especially in combination with immediate breast reconstruction (IBR), and the oncological follow-up. Methods: The medical records of all women who underwent a PM from December 1993 to December 1999 have been reviewed with respect to management, patient characteristics, complications and oncological follow-up. Results: During the study period 1 12 women with a median age of 38.8 years opted for a PM: 76 were germline mutation carriers. After PM, 79 women without breast or ovarian cancer in their medical history, were free of disease after 2.5 years (median). Before PM, 29 women had been treated for breast cancer, 3.9 years (median) previously; 5 of these women had developed metastatic disease by the last consultation. Before PM, 2 patients had been treated for DCIS and 2 patients for ovarian cancer. Four DCIS were found; none of these women had evidence of disease 4.0 years (median) after PM. In 59 women laparoscopic prophylactic bilateral oophorectomy (PBO) was performed; 36 simultaneously with PM and 23 separately. A total of 103 women (92%) opted for IBR. After PM, the complication rate for IBR was 21%: 11% within 6 weeks and 10% at long-term follow-up (median 3.5) after PM, including the removal of 10 prostheses. Conclusions: Women with an increased risk of breast cancer due to a genetic predisposition should be adequately informed about the different treatment options in the setting of a multidisciplinary approach. PM can simultaneously be combined with PBO and IBR. IBR can facilitate the decision to undergo a PM. PM followed by IBR has an acceptable complication rate. (C) 2002 Published by Elsevier Science Ltd.
引用
收藏
页码:627 / 632
页数:6
相关论文
共 26 条
[1]
The genetic basis of breast cancer and its clinical implications [J].
Bennett, IC ;
Gattas, M ;
Teh, BT .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1999, 69 (02) :95-105
[2]
Family history of breast cancer and local recurrence after breast-conserving therapy [J].
Brekelmans, CTM ;
Voogd, AC ;
Botke, G ;
van Geel, BN ;
Rodrigus, P ;
Rutgers, EJT ;
Klijn, JGM ;
Coebergh, JW .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (04) :620-626
[3]
Morbidity of immediate breast reconstruction (IBR) after mastectomy by a subpectorally placed silicone prosthesis: the adverse effect of radiotherapy [J].
Contant, CME ;
van Geel, AN ;
van der Holt, B ;
Griep, C ;
Wai, RTJ ;
Wiggers, T .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2000, 26 (04) :344-350
[4]
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].
Ford, D ;
Easton, DF ;
Stratton, M ;
Narod, S ;
Goldgar, D ;
Devilee, P ;
Bishop, DT ;
Weber, B ;
Lenoir, G ;
Chang-Claude, J ;
Sobol, H ;
Teare, MD ;
Struewing, J ;
Arason, A ;
Scherneck, S ;
Peto, J ;
Rebbeck, TR ;
Tonin, P ;
Neuhausen, S ;
Barkardottir, R ;
Eyfjord, J ;
Lynch, H ;
Ponder, BAJ ;
Gayther, SA ;
Birch, JM ;
Lindblom, A ;
Stoppa-Lyonnet, D ;
Bignon, Y ;
Borg, A ;
Hamann, U ;
Haites, N ;
Scott, RJ ;
Maugard, CM ;
Vasen, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689
[5]
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer [J].
Hartmann, LC ;
Schaid, DJ ;
Woods, JE ;
Crotty, TP ;
Myers, JL ;
Arnold, PG ;
Petty, PM ;
Sellers, TA ;
Johnson, JL ;
McDonnell, SK ;
Frost, MH ;
Jenkins, RB .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) :77-84
[6]
Jameson M B, 1997, Clin Oncol (R Coll Radiol), V9, P119, DOI 10.1016/S0936-6555(05)80450-9
[7]
Survival of BRCA1 breast and ovarian cancer patients:: A population-based study from southern Sweden [J].
Jóhannsson, OT ;
Ranstam, J ;
Borg, Å ;
Olsson, H .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :397-404
[8]
INHERITED BREAST AND OVARIAN-CANCER - WHAT ARE THE RISKS - WHAT ARE THE CHOICES [J].
KING, MC ;
ROWELL, S ;
LOVE, SM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (15) :1975-1980
[9]
Should prophylactic surgery be used in women with a high risk of breast cancer? Pro [J].
Klijn, JGM .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (13) :2149-2153
[10]
Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers [J].
Lee, JS ;
Wacholder, S ;
Struewing, JP ;
McAdams, M ;
Pee, D ;
Brody, LC ;
Tucker, MA ;
Hartge, P .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (03) :259-263